1
|
Nayak S, Bhatt MLB, Goel MM, Gupta S, Mehrotra D, Mahdi AA, Mishra A. Aberrant Expression of PTPN-14 and Wilms’ Tumor 1 as Putative Biomarker for Locoregional Recurrence in Oral Squamous Cell Carcinoma. ASIAN JOURNAL OF ONCOLOGY 2021. [DOI: 10.1055/s-0041-1731128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Abstract
Objective Locoregional recurrence in oral squamous cell carcinoma (OSCC) is a major concern that leads to metastasis. Its detection at earliest stage is very important to increase the overall survival of the patient. There is no any biomarker for locoregional recurrence in oral squamous cell carcinoma (OSCC). The aim of this study was to find a biomarker for locoregional recurrence in tissue and serum at gene and protein level.
Methods This work studied the expression of protein tyrosine phosphatase nonreceptor type 14 (PTPN-14) and Wilms’ tumor 1 (WT-1) in patients and correlated their expression with locoregional recurrence and survival. Tissue expression was observed in formalin fixed tissue biopsies of 96 OSCC and 32 healthy controls by immunohistochemistry using antibody against PTPN-14 and WT-1 and serum level was estimated by enzyme-linked immunosorbent assay in pre- and post-chemoradiotherapy samples. mRNA expression was determined by using real-time polymerase chain reaction. Patients were followed for 3 years for locoregional recurrence.
Results Expression of PTPN-14 and WT-1 in OSCC was upregulated (aberrant) in tissue and sera in both gene and protein level as compared with healthy controls. Locoregional recurrence was observed in 10 (23.80%) patients and significantly associated with PTPN-14 (p < 0.047) and WT-1 expression (p < 0.031).
Conclusion PTPN-14 and WT-1 may be used as biomarker to identify patients for higher risk of locoregional recurrence. This study drove molecular aspect and phenotypic level to derive new emergent strategies in future for recurrent OSCC.
Collapse
Affiliation(s)
- Seema Nayak
- Department of Radiotherapy, King George’s Medical University, Lucknow, Uttar Pradesh, India
- Medanta Holding Pvt. Ltd., Lucknow, Uttar Pradesh, India
| | - Madan Lal Brahma Bhatt
- Department of Radiotherapy, King George’s Medical University, Lucknow, Uttar Pradesh, India
| | - Madhu Mati Goel
- Medanta Holding Pvt. Ltd., Lucknow, Uttar Pradesh, India
- Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
| | - Seema Gupta
- Department of Radiotherapy, King George’s Medical University, Lucknow, Uttar Pradesh, India
| | - Divya Mehrotra
- Department of Oral and Maxillofacial Surgery, King George’s Medical University, Lucknow, Uttar Pradesh, India
| | - Abbas Ali Mahdi
- Department of Biochemistry, King George’s Medical University, Lucknow, Uttar Pradesh, India
| | - Anupam Mishra
- Department of Otorhinolaryngology, King George’s Medical University, Lucknow, Uttar Pradesh, India
| |
Collapse
|
2
|
Bologna-Molina R, Takeda Y, Kuga T, Chosa N, Kitagawa M, Takata T, Ishisaki A, Mikami T. Expression of Wilms' tumor 1 (WT1) in ameloblastomas. J Oral Sci 2016; 58:407-13. [PMID: 27665981 DOI: 10.2334/josnusd.15-0546] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The Wilms' tumor 1 gene (WT1) was originally isolated and described as the gene responsible for Wilms' tumor. Although there is growing evidence linking the overexpression of WT1 to tumorigenesis, no reports on ameloblastoma are available at present. The aim of this study was to examine the expression of WT1 in various histological subtypes of ameloblastoma tissue specimens and in human ameloblastoma cell lines. Immunohistochemical analyses were performed on a total of 168 cases of ameloblastoma, one case of ameloblastic carcinoma, and five cases of tooth germs (control). Three immortalized human dental epithelial cell lines (HAM1, HAM2, and HAM3) derived from the same ameloblastoma patient were used for reverse transcription-polymerase chain reaction (RT-PCR) and western blot assays. The tooth germs did not express WT1 (0%), and more than half of the ameloblastoma cases showed WT1 overexpression (54.7%). Immunoreactivity of solid-type ameloblastoma (76.1%) was more evident than that of unicystic-type ameloblastoma (40.9%). The expression level of WT1 mRNA in HAM2 was higher than that in HAM1 (moderate) and HAM3 (weak), showing the heterogeneity of tumor cells. The WT1 protein was strongly detected in HAM2 and minimally detected in HAM1 and HAM3. Our results suggest that WT1 expression influences the pathogenesis of ameloblastoma by varying its expression level in different histological types. (J Oral Sci 58, 407-413, 2016).
Collapse
|
3
|
Li X, Ottosson S, Wang S, Jernberg E, Boldrup L, Gu X, Nylander K, Li A. Wilms' tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck. BMC Cancer 2015; 15:342. [PMID: 25929687 PMCID: PMC4421988 DOI: 10.1186/s12885-015-1356-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Accepted: 04/23/2015] [Indexed: 12/15/2022] Open
Abstract
Background Wilms’ tumor gene 1 (WT1) can act as a suppressor or activator of tumourigenesis in different types of human malignancies. The role of WT1 in squamous cell carcinoma of the head and neck (SCCHN) is not clear. Overexpression of WT1 has been reported in SCCHN, suggesting a possible oncogenic role for WT1. In the present study we aimed at investigating the function of WT1 and its previously identified protein partners p63 and p53 in the SCCHN cell line FaDu. Methods Silencing RNA (siRNA) technology was applied to knockdown of WT1, p63 and p53 in FaDu cells. Cell proliferation was detected using MTT assay. Chromatin immunoprecipitation (ChIP)/PCR analysis was performed to confirm the effect of WT1 on the p63 promoter. Protein co-immunoprecipitation (co-IP) was used to find protein interaction between WT1 and p53/p63. Microarray analysis was used to identify changes of gene expression in response to knockdown of either WT1 or p63. WT1 RNA level was detected using real-time quantitative PCR (RT-qPCR) in patients with SCCHN. Results We found that WT1 and p63 promoted cell proliferation, while mutant p53 (R248L) possessed the ability to suppress cell proliferation. We reported a novel positive correlation between WT1 and p63 expression. Subsequently, p63 was identified as a WT1 target gene. Furthermore, expression of 18 genes involved in cell proliferation, cell cycle regulation and DNA replication was significantly altered by downregulation of WT1 and p63 expression. Several known WT1 and p63 target genes were affected by WT1 knockdown. Protein interaction was demonstrated between WT1 and p53 but not between WT1 and p63. Additionally, high WT1 mRNA levels were detected in SCCHN patient samples. Conclusions Our findings suggest that WT1 and p63 act as oncogenes in SCCHN, affecting multiple genes involved in cancer cell growth. Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1356-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Xingru Li
- Department of Medical Biosciences, Clinical Chemistry, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| | - Sofia Ottosson
- Department of Medical Biosciences, Clinical Chemistry, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| | - Sihan Wang
- Department of Medical Biosciences, Clinical Chemistry, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| | - Emma Jernberg
- Department of Medical Biosciences, Pathology, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| | - Linda Boldrup
- Department of Medical Biosciences, Pathology, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| | - Xiaolian Gu
- Department of Medical Biosciences, Pathology, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| | - Karin Nylander
- Department of Medical Biosciences, Pathology, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| | - Aihong Li
- Department of Medical Biosciences, Clinical Chemistry, Umeå University, By 6 M, 2nd floor, Umeå, 90185, Sweden.
| |
Collapse
|
4
|
Rather MI, Swamy S, Gopinath KS, Kumar A. Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics. J Biol Chem 2014; 289:968-76. [PMID: 24257751 PMCID: PMC3887219 DOI: 10.1074/jbc.m113.483255] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Revised: 11/19/2013] [Indexed: 01/25/2023] Open
Abstract
The Wilms tumor 1 gene (WT1) can either repress or induce the expression of genes. Inconsistent with its tumor suppressor role, elevated WT1 levels have been observed in leukemia and solid tumors. WT1 has also been suggested to act as an oncogene by inducing the expression of MYC and BCL-2. However, these are only the correlational studies, and no functional study has been performed to date. Consistent with its tumor suppressor role, CDC73 binds to RNA polymerase II as part of a PAF1 transcriptional regulatory complex and causes transcriptional repression of oncogenes MYC and CCND1. It also represses β-catenin-mediated transcription. Based on the reduced level of CDC73 in oral squamous cell carcinoma (OSCC) samples in the absence of loss-of-heterozygosity, promoter methylation, and mutations, we speculated that an inhibitory transcription factor is regulating its expression. The bioinformatics analysis predicted WT1 as an inhibitory transcription factor to regulate the CDC73 level. Our results showed that overexpression of WT1 decreased CDC73 levels and promoted proliferation of OSCC cells. ChIP and EMSA results demonstrated binding of WT1 to the CDC73 promoter. The 5-azacytidine treatment of OSCC cells led to an up-regulation of WT1 with a concomitant down-regulation of CDC73, further suggesting regulation of CDC73 by WT1. Exogenous CDC73 attenuated the protumorigenic activity of WT1 by apoptosis induction. An inverse correlation between expression levels of CDC73 and WT1 was observed in OSCC samples. These observations indicated that WT1 functions as an oncogene by repressing the expression of CDC73 in OSCC. We suggest that targeting WT1 could be a therapeutic strategy for cancer, including OSCC.
Collapse
Affiliation(s)
- Mohammad Iqbal Rather
- From the Department of Molecular Reproduction, Development, and Genetics, Indian Institute of Science, Bangalore 560012, India and
| | - Shivananda Swamy
- the Department of Surgical Oncology, HCG Bangalore Institute of Oncology, Bangalore 560027, India
| | - Kodaganur S. Gopinath
- the Department of Surgical Oncology, HCG Bangalore Institute of Oncology, Bangalore 560027, India
| | - Arun Kumar
- From the Department of Molecular Reproduction, Development, and Genetics, Indian Institute of Science, Bangalore 560012, India and
| |
Collapse
|